JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 22, 2004; DOI: 10.1124/jpet.104.069658


0022-3565/04/3112-485-491$20.00
JPET 311:485-491, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.069658v1
311/2/485    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pacher, P.
Right arrow Articles by Szabó, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pacher, P.
Right arrow Articles by Szabó, C.

CARDIOVASCULAR

A New, Potent Poly(ADP-ribose) Polymerase Inhibitor Improves Cardiac and Vascular Dysfunction Associated with Advanced Aging

Pál Pacher, Anne Vaslin, Rita Benko, Jon G. Mabley, Lucas Liaudet, György Haskó, Anita Marton, Sándor Bátkai, Márk Kollai, and Csaba Szabó

Inotek Pharmaceuticals Corporation, Beverly, Massachusetts (P.P., A.V., R.B., J.G.M., A.M., C.S.); Laboratory of Physiologic Studies, National Institute on Alcohol Abuse & Alcoholism, National Institutes of Health, Bethesda, Maryland (P.P., S.B.); Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary (G.H.); Department of Pharmacology and Pharmacotherapy (P.P.) and Institute of Human Physiology and Clinical Experimental Research (R.B., M.K., C.S.), Semmelweis University, Budapest, Hungary; Critical Care Division, Department of Internal Medicine, University Hospital, Lausanne, Switzerland (L.L.); and Department of Surgery, University of Medicine and Dentistry, New Jersey Medical School, Newark, New Jersey (G.H., C.S.)

Increased production of reactive oxygen and nitrogen species has recently been implicated in the pathogenesis of cardiac and endothelial dysfunction associated with atherosclerosis, hypertension, and aging. Oxidant-induced cell injury triggers the activation of nuclear enzyme poly(ADP-ribose) polymerase (PARP), which in turn contributes to cardiac and vascular dysfunction in various pathophysiological conditions including diabetes, reperfusion injury, circulatory shock, and aging. Here, we investigated the effect of a new PARP inhibitor, INO-1001, on cardiac and endothelial dysfunction associated with advanced aging using Millar's new Aria pressure-volume conductance system and isolated aortic rings. Young adult (3 months old) and aging (24 months old) Fischer rats were treated for 2 months with vehicle, or the potent PARP inhibitor INO-1001. In the vehicle-treated aging animals, there was a marked reduction of both systolic and diastolic cardiac function and loss of endothelial relaxant responsiveness of aortic rings to acetylcholine. Treatment with INO-1001 improved cardiac performance in aging animals and also acetylcholine-induced, nitric oxide-mediated vascular relaxation. Thus, pharmacological inhibition of PARP may represent a novel approach to improve cardiac and vascular dysfunction associated with aging.


Received April 7, 2004; accepted June 22, 2004.

Address correspondence to: Dr. Pál Pacher, National Institutes of Health, National Institute on Alcohol Abuse & Alcoholism, Park Bldg., Rm. 445, 12420 Parklawn Drive, MSC-8115, Bethesda, MD 20892-8115. E-mail: pacher{at}mail.nih.gov




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
T. Radovits, J. Zotkina, L.-N. Lin, T. Bomicke, R. Arif, D. Gero, E. M. Horvath, M. Karck, C. Szabo, and G. Szabo
Poly(ADP-Ribose) Polymerase Inhibition Improves Endothelial Dysfunction Induced by Hypochlorite
Experimental Biology and Medicine, October 1, 2007; 232(9): 1204 - 1212.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Batkai, P. Mukhopadhyay, J. Harvey-White, R. Kechrid, P. Pacher, and G. Kunos
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1689 - H1695.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Batkai, M. Rajesh, P. Mukhopadhyay, G. Hasko, L. Liaudet, B. F. Cravatt, A. Csiszar, Z. Ungvari, and P. Pacher
Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H909 - H918.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev, January 1, 2007; 87(1): 315 - 424.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. M. Alwardt, Q. Yu, H. L. Brooks, M. R. McReynolds, R. Vazquez, R. R. Watson, and D. F. Larson
Comparative effects of dehydroepiandrosterone sulfate on ventricular diastolic function with young and aged female mice
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R251 - R256.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.